Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor

NCT01942356 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2015-01-27

No results posted yet for this study

Summary

The purpose of this study is to compare a closed-loop intravenous anesthetic using Bispectral Index as a feedback loop and a controller based on reinforcement learning to titrate dose and intravenous anesthetic that is manually controlled or a standard volatile anesthetic agent titrated by the anesthesiologist to determine improvement in the following parameters as compared to controls: time to discharge from the Post Anesthesia Care Unit, post-operative nausea and vomiting, pain scores and sedation scores.

Conditions

  • Acute Cholecystitis
  • Chronic Cholecystitis

Interventions

PROCEDURE

TIVA - Hypotension

Defined as: MAP \< 70% of baseline Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event. 1. Give 200 mL Fluid Bolus 2. If not successful, give ephedrine 5 mg bolus 3. Repeat from 1.) if even is not resolved after 3.)

PROCEDURE

TIVA - Hypertension

Defined as: SBP \> 130% of baseline sustained for 2 readings Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event. 1.) Labetalol 5 mg IV will be administered

PROCEDURE

TIVA - Bradycardia

Defined as: Heart rate \< 45 beats/min 1.) Bolus of 0.2 mg glycopyrrolate

PROCEDURE

TIVA - Tachycardia

Defined as: Heart Rate \> 90 beats/min 1. If associated with normal NIBP (MAP \> 60 mmHg and SAP \< 140): give fluid bolus of 200 mL, repeat once if required. Look for bleeding and treat if required. 2. If associated with hypertension (SAB \> 140 mmHg): proceed with the management of the hypotention during maintenance protocol. 3. If associated with hypotension (MAP \< 60 mmHg): proceed with the management of the hypotnetion during maintenance protocol.

PROCEDURE

INH - Hypotension

Defined as: MAP \< 70 % of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event. 1. give a 200 ml fluid bolus (crystalloid). 2. If not successful, give ephedrine 5 mg bolus. 3. If not successful decrease volatile by 0.1 MAC. 4. Repeat from 1) if event is not resolved after step 3) for maximum of 2 iterations

PROCEDURE

INH - Hypertension

Defined as: SBP \> 130% of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event. 1. increase Sevoflurane by 0.1 MAC 2. If not successful after 3 minutes (SBP \>130% of baseline), increase Sevoflurane again by 0.1 MAC. Maximum of 1.2 allowed. 3. If still not successful (SBP \>130% of baseline), Labetolol 5mg IV will be administered.

PROCEDURE

INH - Bradycardia

Defined as: Heart Rate \< 45 beats/min 1.) Bolus of 0.2 mg glycopyrrolate

PROCEDURE

INH - Tachycardia

Defined as: Heart rate \> 90 beats/min 1. if associated with normal NIBP (MAP \> 70% of baseline and SBP \<130% of baseline) : give fluid bolus of 200 ml, repeat once if required. (look for bleeding and treat if required). 2. If associated with hypertension (SBP \>130% of baseline) : proceed with the management of the hypertension during maintenance protocol. 3. If associated with hypotension (MAP \< 70% of baseline) : proceed with the management of the hypotension during maintenance protocol.

Sponsors & Collaborators

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Erik Boatman, M.D. · University of Texas

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-04-30
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01942356 on ClinicalTrials.gov